Humoral autoimmune responses to glutamic acid decarboxylase have similar target epitopes and subclass that show titer-dependent disease association
- 1 October 2005
- journal article
- research article
- Published by Elsevier in Clinical Immunology
- Vol. 117 (1) , 31-35
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- High-resolution autoreactive epitope mapping and structural modeling of the 65 kDa form of human glutamic acid decarboxylaseJournal of Molecular Biology, 1999
- IA-2-autoantibodies complement GAD 65 -autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblingsDiabetologia, 1997
- Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivityDiabetologia, 1995
- Two distinct glutamic acid decarboxylase auto-antibody specificities in IDDM target different epitopesDiabetes, 1995
- Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunityDiabetes, 1994
- Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus.Journal of Experimental Medicine, 1994
- Association of HLA-DQB1*0201 with stiff-man syndromeThe Journal of Clinical Endocrinology & Metabolism, 1993
- The structural and functional heterogeneity of glutamic acid decarboxylase: A reviewNeurochemical Research, 1991
- Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylaseNature, 1990
- Autoantibodies to Glutamic Acid Decarboxylase in a Patient with Stiff-Man Syndrome, Epilepsy, and Type I Diabetes MellitusNew England Journal of Medicine, 1988